Non-Small Cell Lung Cancer with EGFR and HER2 Alterations
Clinical research in advanced non-small cell lung cancer focuses on tumours carrying EGFR or HER2 mutations, including EGFR exon 20 insertion variants and locally advanced or metastatic disease. The sponsor’s activity in this area reflects a strong interest in molecularly defined lung cancer populations and targeted treatment options.
- EGFR-mutated lung cancer
- HER2-mutated lung cancer
- EGFR exon 20 insertion
- Metastatic disease
Research sites across multiple countries support treatment development for patients whose disease is defined by specific oncogenic drivers in the respiratory oncology setting.
Targeted Therapy in Thoracic Oncology
The sponsor is active in studies of oral targeted therapies for lung cancer, with emphasis on agents designed to address resistant mutation profiles and broaden options in thoracic malignancies. This includes investigation of treatment activity in previously untreated and treatment-experienced populations.
- Mutation-directed treatment
- Thoracic malignancies
- Oral anticancer therapy
- Treatment-resistant disease
These studies are centered on precision approaches for patients with oncogenic driver alterations in lung cancer.
Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Another key area of interest is relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, where the sponsor is examining therapies for persistent B-cell malignancies. This reflects involvement in hematologic cancer research alongside solid tumour programs.
- Relapsed/refractory CLL
- SLL
- B-cell malignancies
- Hematologic oncology
The hematology portfolio extends the sponsor’s research focus beyond lung cancer into lymphoid neoplasms with high unmet clinical need.
Oncology Drug Development and Antitumor Activity
Across its clinical program, the sponsor is engaged in evaluating antitumor efficacy, safety, and tolerability in oncology populations. The research landscape includes comparative studies in non-small cell lung cancer and blood cancers, with a clear focus on clinically actionable endpoints in cancer treatment.
- Antitumor efficacy
- Safety and tolerability
- Comparative oncology research
- Precision cancer medicine
These programs contribute to the development of therapies for molecularly selected cancer groups in both solid and hematologic oncology.
